What is it about?
This study investigates how a common HIV medication, tenofovir, may contribute to kidney damage in adults receiving care at Zambia’s largest referral hospital. By analyzing clinical data from HIV-positive patients, the research identifies patterns of kidney dysfunction and highlights the need for improved monitoring and alternative treatment strategies. The findings aim to support safer HIV care and inform national health policies.
Featured Image
Photo by julien Tromeur on Unsplash
Why is it important?
Tenofovir is commonly used to treat HIV in sub-Saharan Africa, but its risk of causing kidney problems is often overlooked. This study from Zambia sheds light on this issue and could help change treatment guidelines, making it safer for patients and possibly preventing long-term health issues. It also plays a part in improving HIV care in areas that have limited resources.
Perspectives
As someone who studies infectious diseases and works in medical science, I see this research as an important step forward in understanding how HIV treatment can affect the kidneys. The findings show that it’s important to regularly check kidney health when treating HIV, especially in places where tenofovir is commonly used. This study helps improve how we care for patients and reminds us that doctors, lab experts, and health leaders need to work together to make HIV treatment safer and more effective, especially in Zambia and other regions facing similar challenges.
Edgar Muchinta
Ministry of Health/ National Heart Hospital, Levy Mwanawasa Medical University
Read the Original
This page is a summary of: Chronic kidney disease among HIV-positive Zambian adults with tenofovir-associated nephrotoxicity at University Teaching Hospital (UTH) in Lusaka, PLOS One, August 2025, PLOS,
DOI: 10.1371/journal.pone.0330356.
You can read the full text:
Contributors
The following have contributed to this page
